Genentech’s Next Move

Genentech’s Next Move
Genentech stunned the cancer world last week with news that its Avastin colon cancer drug extended patients’ lives by five months, proving wrong skeptics who said the blood vessel-blocking drug would never work. Now the biotech pioneer is embarking on a bold strategy to dominate the cancer drug market for decades to come by combining drugs even before they are approved.


Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Subscribe!